Payment overview · 2025
General Payments
$352.51
16 reported records · 9 companies
Healthcare provider profile · identity verified
Andrew Warren Wunderlich, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JOLIET, IL · NPI 1275528341
Verified facts
What the public records show
CMS Open Payments records show Andrew Warren Wunderlich, M.D. received $352.51 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Mounjaro, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $109.89 | 31.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.39 | 18.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.00 | 9.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.17 | 9.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.17 | 6.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.89 | 6.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.22 | 6.0% | 1 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $20.40 | 5.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.38 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $352.51 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $93.04 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $76.90 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $64.39 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.17 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 91 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
91 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 428 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 369 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 344 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 267 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 231 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 66 |
| Montelukast Sodium | Montelukast Sodium | 221 | 79 |
| Furosemide | Furosemide | 203 | 62 |
| Losartan Potassium | Losartan Potassium | 192 | 58 |
| Gabapentin | Gabapentin | 178 | 63 |
| Alprazolam | Alprazolam | 177 | 43 |
| Lisinopril | Lisinopril | 166 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 42 |
| Allopurinol | Allopurinol | 150 | 45 |
| Metformin Hcl | Metformin Hcl | 146 | 49 |
| Meloxicam | Meloxicam | 144 | 50 |
| Potassium Chloride | Potassium Chloride | 143 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 36 |
| Eliquis | Apixaban | 141 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 140 | 38 |
| Metformin Hcl Er | Metformin Hcl | 122 | 35 |
| Omeprazole | Omeprazole | 115 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 48 |
| Carvedilol | Carvedilol | 113 | 33 |
| Pregabalin | Pregabalin | 104 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 27 |
| Spironolactone | Spironolactone | 95 | 24 |
| Mounjaro | Tirzepatide | 91 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 30 |
| Simvastatin | Simvastatin | 82 | 23 |
| Prednisone | Prednisone | 79 | 57 |
| Azithromycin | Azithromycin | 76 | 60 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 24 |
| Tramadol Hcl | Tramadol Hcl | 71 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 31 |
| Finasteride | Finasteride | 65 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 21 |
| Glimepiride | Glimepiride | 62 | 21 |
| Propranolol Hcl | Propranolol Hcl | 62 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 20 |
| Lorazepam | Lorazepam | 58 | suppressed |
| Ezetimibe | Ezetimibe | 57 | 20 |
| Trazodone Hcl | Trazodone Hcl | 57 | 24 |
| Levofloxacin | Levofloxacin | 53 | 40 |
| Sucralfate | Sucralfate | 53 | 18 |
| Memantine Hcl | Memantine Hcl | 52 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 13 |
| Methylprednisolone | Methylprednisolone | 49 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 13 |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 28 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | 14 |
| Ondansetron Odt | Ondansetron | 46 | 26 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Nystatin | Nystatin | 43 | 12 |
| Jardiance | Empagliflozin | 42 | 14 |
| Sertraline Hcl | Sertraline Hcl | 42 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 21 |
| Donepezil Hcl | Donepezil Hcl | 39 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 17 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 14 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Lactulose | Lactulose | 29 | 11 |
| Telmisartan | Telmisartan | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | 11 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 22 |
| Amoxicillin | Amoxicillin | 26 | 11 |
| Clonidine Hcl | Clonidine Hcl | 26 | 13 |
| Mupirocin | Mupirocin | 26 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | 15 |
| Fluconazole | Fluconazole | 25 | 15 |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Metronidazole | Metronidazole | 23 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Procto-Med Hc | Hydrocortisone | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Cefdinir | Cefdinir | 20 | 11 |
| Colchicine | Colchicine | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 11 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $352.51 · 16 records | ABBVIE INC. | AREXVY, Auvelity, BREZTRI, CREON, Dexcom G6 Transmitter, FARXIGA, Grastek, LINZESS, MOUNJARO, Odactra, Ozempic, QULIPTA, Ragwitek, Rybelsus, SHINGRIX, SYNTHROID, The Cologuard Plus Collection Kit, UBRELVY | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error